

Special Issue

Endocarditis of the Heart: An Overview of Current Knowledge on Epidemiology, Pathogenesis, Diagnosis and Treatment

Message from the Guest Editor

Infective endocarditis (IE) is a consequence of the localized or systemic diffusion of pathogens, generally bacteria or fungi, in the heart. Complications of heart valve endocarditis (HVE) develop in approximately 1% to 43% of patients. Staphylococcal contamination increasingly occurs with nosocomial infection, with additional burden brought about by antibiotic multiresistance. The introduction of two vaccines has unfortunately failed to resolve these issues, as they demonstrated a lack of safety and effectiveness in Phase III clinical studies. The biological and immunological mechanisms that determine resistance require further investigation.

Thus, the publication of peer-reviewed clinical and research articles, fostering immunological and pathogenetic-level knowledge, are urgently needed to improve consensus and, consequently, to guide appropriate diagnostic and clinical choices. Papers may address: prevention of infective endocarditis in the 21st century; antibiotic prophylaxis and its effect; diagnosis: imaging and microbiology; and shared multidisciplinary decision-making processes in medical therapeutic orientation.

Guest Editor

Dr. Francesco Nappi

Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France

Deadline for manuscript submissions

closed (15 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/120912

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).